SFA — Sopharma AD Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesBalancedMid CapHigh Flyer

Annual income statement for Sopharma AD, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	fx Final	fx Final	fx Final	fx Final	fx Final
Revenue
Total Revenue	826	857	969	1,101	1,350
Cost of Revenue
Gross Profit	159	166	193	215	290
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	800	823	920	1,060	1,279
Operating Profit	26.4	33.9	48.5	41.4	71.1
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	49.9	43.5	56.9	47.1	80.4
Provision for Income Taxes
Net Income After Taxes	46.9	39	51.1	41.1	72.4
Minority Interest
Net Income Before Extraordinary Items
Net Income	45.8	36.4	49.1	39	68.3
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	45.8	36.4	49.1	39	68.3
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.094	0.13	0.121	0.081	0.344
Dividends per Share